It was a pleasure to meet with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to discuss the findings from the COUGH-1 and COUGH-2 studies, investigating gefapixant for the treatment of patients with chronic cough.
The abstract ‘Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant.’ (Presentation ID 1588) was presented at ERS International Congress 2021, 5-8 September 2021.
Questions
- How were patient reported cough severity outcomes measured in the COUGH-1 and COUGH-2 studies? (0:15)
- What were the aims, design and inclusion criteria of the COUGH-1 and COUGH-2 studies? (0:48)
- What were the findings from the main study periods? (1:32)
- Were these findings maintained in the extension periods up to 52 weeks? (1:56)
Disclosures: Peter Dicpinigaitis is a consultant to Merck, who sponsored the research discussed in the interview.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
